{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T13:48:04Z","timestamp":1764510484394},"reference-count":51,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,12,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a unique diagnostic entity, with only \u223c 500 new cases in the United States per year with a similar infrequent incidence worldwide. NLPHL also has distinctive pathobiology and clinical characteristics compared with the more common classical Hodgkin lymphoma (cHL), including CD20 positivity of the pathognomic lymphocytic and histiocytic cells and an overall more indolent course with a higher likelihood of delayed relapses. Given the limited numbers of prospective NLPHL-focused trials, management algorithms historically have typically been centered on retrospective data with guidelines often adopted from cHL and indolent B-cell lymphoma treatment approaches. Key recent publications have delineated that NLPHL has a higher level of pathological overlap with cHL and the aggressive B-cell lymphomas than with indolent B-cell lymphomas. Over the past decade, there has been a series of NLPHL publications that evaluated the role of rituximab in the frontline and relapsed setting, described the relative incidence of transformation to aggressive B-cell lymphomas, weighed the benefit of addition of chemotherapy to radiation treatment for patients with early-stage disease, considered what should be the preferred chemotherapy regimen for advanced-stage disease, and even assessed the potential role of autologous stem cell transplantation for the management of relapsed disease. General themes within the consensus guidelines include the role for radiation treatment as a monotherapy for early-stage disease, the value of large B-cell lymphoma\u2013directed regimens for transformed disease, the utility of rituximab for treatment of relapsed disease, and, in the pediatric setting, the role of surgical management alone for patients with early-stage disease.<\/jats:p>","DOI":"10.1182\/asheducation-2013.1.406","type":"journal-article","created":{"date-parts":[[2013,12,6]],"date-time":"2013-12-06T15:51:13Z","timestamp":1386345073000},"page":"406-413","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":12,"title":["Lymphocyte-predominant Hodgkin lymphoma: what is the optimal treatment?"],"prefix":"10.1182","volume":"2013","author":[{"given":"Michelle","family":"Fanale","sequence":"first","affiliation":[{"name":"MD Anderson Cancer Center, University of Texas, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"1","key":"2019111703541024300_B1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3322\/caac.21166","article-title":"Cancer statistics, 2013","volume":"63","author":"Siegel","year":"2013","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"2019111703541024300_B2","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1056\/NEJM194601102340201","article-title":"Hodgkin's disease: clinical diagnosis","volume":"234","author":"Jackson","year":"1946","journal-title":"N Engl J Med"},{"issue":"4","key":"2019111703541024300_B3","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1056\/NEJM194601242340401","article-title":"Hodgkin's disease: treatment and prognosis","volume":"234","author":"Jackson","year":"1946","journal-title":"N Engl J Med"},{"key":"2019111703541024300_B4","volume-title":"Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. WHO Classification of Tumours","author":"Jaffe","year":"2001"},{"issue":"6","key":"2019111703541024300_B5","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1046\/j.1365-2559.1996.d01-473.x","article-title":"Malignant lymphomas with a follicular growth pattern","volume":"28","author":"Isaacson","year":"1996","journal-title":"Histopathology"},{"issue":"2","key":"2019111703541024300_B6","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1182\/blood.V87.2.465.bloodjournal872465","article-title":"Distinctive expression pattern of the BCL-6 protein in nodular lymphocyte predominance Hodgkin's disease","volume":"87","author":"Falini","year":"1996","journal-title":"Blood"},{"issue":"5","key":"2019111703541024300_B7","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/path.1746","article-title":"Differential expression of activation-induced cytidine deaminase (AID) in nodular lymphocyte-predominant and classical Hodgkin lymphoma","volume":"205","author":"Greiner","year":"2005","journal-title":"J Pathol"},{"issue":"3","key":"2019111703541024300_B8","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1365-2559.2005.02317.x","article-title":"Loss of CD19 expression in B-cell neoplasms","volume":"48","author":"Masir","year":"2006","journal-title":"Histopathology"},{"issue":"6","key":"2019111703541024300_B9","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1097\/00000478-200006000-00010","article-title":"CD10 and BCL-6 expression in paraffin sections of normal lymphoid tissue and B-cell lymphomas","volume":"24","author":"Dogan","year":"2000","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"2019111703541024300_B10","first-page":"457","article-title":"Nodular lymphocyte predominance type of Hodgkin's disease is a germinal center lymphoma","volume":"54","author":"Timens","year":"1986","journal-title":"Lab Invest"},{"issue":"10","key":"2019111703541024300_B11","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1084\/jem.20080809","article-title":"Origin and pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis","volume":"205","author":"Brune","year":"2008","journal-title":"J Exp Med"},{"issue":"9","key":"2019111703541024300_B12","doi-asserted-by":"crossref","first-page":"3387","DOI":"10.1182\/blood-2007-03-082511","article-title":"Somatic hypermutation of SOCS1 in lymphocyte-predominant Hodgkin lymphoma is accompanied by high JAK2 expression and activation of STAT6","volume":"110","author":"Mottok","year":"2007","journal-title":"Blood"},{"issue":"1","key":"2019111703541024300_B13","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3324\/haematol.2009.010157","article-title":"Mutations in the genes coding for the NF-\u03baB regulating factors I\u03baB\u03b1 and A20 are uncommon in nodular lymphocyte-predominant Hodgkin's lymphoma","volume":"95","author":"Schumacher","year":"2010","journal-title":"Haematologica"},{"issue":"3","key":"2019111703541024300_B14","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood-2005-10-3949","article-title":"Aberrant somatic hypermutation in tumor cells of nodular-lymphocyte-predominant and classic Hodgkin lymphoma","volume":"108","author":"Liso","year":"2006","journal-title":"Blood"},{"issue":"5","key":"2019111703541024300_B15","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1309\/Y8KD32QGRYFN1XQX","article-title":"A double-positive CD4+CD8+ T-cell population is commonly found in nodular lymphocyte predominant Hodgkin lymphoma","volume":"126","author":"Rahemtullah","year":"2006","journal-title":"Am J Clin Pathol"},{"issue":"3","key":"2019111703541024300_B16","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1365-2141.2010.08528.x","article-title":"Analysis of KLHDC8B in familial nodular lymphocyte predominant Hodgkin lymphoma","volume":"154","author":"Saarinen","year":"2011","journal-title":"Br J Haematol"},{"issue":"11","key":"2019111703541024300_B17","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1080\/10428190500236502","article-title":"Familial nodular lymphocyte predominant Hodgkin lymphoma: Successful treatment with CHOP plus rituximab","volume":"46","author":"Unal","year":"2005","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2019111703541024300_B18","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/j.1365-2141.2005.05672.x","article-title":"Clustering and anticipation for nodular lymphocyte predominance Hodgkin lymphoma within a French Basque kindred","volume":"130","author":"Bauduer","year":"2005","journal-title":"Br J Haematol"},{"issue":"3","key":"2019111703541024300_B19","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1080\/10428190310001602354","article-title":"Nodular lymphocyte predominant Hodgkin lymphoma in siblings","volume":"45","author":"Campbell","year":"2004","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"2019111703541024300_B20","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1182\/blood-2011-03-341560","article-title":"Exome sequencing reveals germline NPAT mutation as a candidate risk factor for Hodgkin lymphoma","volume":"118","author":"Saarinen","year":"2011","journal-title":"Blood"},{"issue":"7","key":"2019111703541024300_B21","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1200\/JCO.2012.43.5958","article-title":"High familial risk in nodular lymphocyte-predominant Hodgkin lymphoma","volume":"31","author":"Saarinen","year":"2013","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111703541024300_B22","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1200\/JCO.2007.11.8869","article-title":"Lymphocyte-Predominant and Classical Hodgkin's Lymphoma: A Comprehensive Analysis From the German Hodgkin Study Group","volume":"26","author":"Nogov\u00e1","year":"2008","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111703541024300_B23","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1200\/JCO.1999.17.3.776","article-title":"Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease","volume":"17","author":"Diehl","year":"1999","journal-title":"J Clin Oncol"},{"issue":"17","key":"2019111703541024300_B24","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1182\/blood-2011-07-365932","article-title":"Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome","volume":"118","author":"Savage","year":"2011","journal-title":"Blood"},{"issue":"15","key":"2019111703541024300_B25","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1200\/JCO.2003.01.079","article-title":"Lymphocyte-predominant Hodgkin's lymphoma in children: therapeutic abstention after initial lymph node resection\u2013a Study of the French Society of Pediatric Oncology","volume":"21","author":"Pellegrino","year":"2003","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111703541024300_B26","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1002\/cncr.21303","article-title":"Long-term outcome after radiotherapy alone for lymphocyte-predominant Hodgkin lymphoma: a retrospective multicenter study of the Australasian Radiation Oncology Lymphoma Group","volume":"104","author":"Wirth","year":"2005","journal-title":"Cancer"},{"issue":"5","key":"2019111703541024300_B27","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/00130404-200209000-00008","article-title":"Radiotherapy alone for lymphocyte-predominant Hodgkin's disease","volume":"8","author":"Schlembach","year":"2002","journal-title":"Cancer J"},{"issue":"1","key":"2019111703541024300_B28","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1200\/JCO.2009.24.0945","article-title":"Early-stage, lymphocyte-predominant Hodgkin's lymphoma: patient outcomes from a large, single-institution series with long follow-up","volume":"28","author":"Chen","year":"2010","journal-title":"J Clin Oncol"},{"issue":"10","key":"2019111703541024300_B29","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1093\/annonc\/mdi323","article-title":"Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG)","volume":"16","author":"Nogova","year":"2005","journal-title":"Ann Oncol"},{"issue":"6","key":"2019111703541024300_B30","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1002\/cncr.10404","article-title":"European Organization for Research and Treatment of Cancer and Groupe d'Etude des Lymphomes de l'Adulte very favorable and favorable, lymphocyte-predominant Hodgkin disease","volume":"94","author":"Wilder","year":"2002","journal-title":"Cancer"},{"issue":"11","key":"2019111703541024300_B31","first-page":"2471","article-title":"Treatment of children and adolescents with early stage nodular lymphocyte predominant Hodgkin lymphoma with a low intensity short duration chemotherapy regimen (CVP)\u2013on behalf of the EuroNet-PHL Group [abstract]","volume":"108","author":"Shankar","year":"2006","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"9","key":"2019111703541024300_B32","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1182\/blood-2004-02-0567","article-title":"Comparison of initial characteristics and long-term outcome of patients with lymphocyte-predominant Hodgkin lymphoma and classical Hodgkin lymphoma at clinical stages IA and IIA prospectively treated by brief anthracycline-based chemotherapies plus extended high-dose irradiation","volume":"104","author":"Feugier","year":"2004","journal-title":"Blood"},{"issue":"1","key":"2019111703541024300_B33","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1182\/blood-2007-03-078725","article-title":"Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG)","volume":"111","author":"Schulz","year":"2008","journal-title":"Blood"},{"issue":"11","key":"2019111703541024300_B34","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1182\/blood-2002-08-2644","article-title":"Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial","volume":"101","author":"Ekstrand","year":"2003","journal-title":"Blood"},{"issue":"16","key":"2019111703541024300_B35","doi-asserted-by":"crossref","first-page":"4363","DOI":"10.1182\/blood-2011-06-361055","article-title":"Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group","volume":"118","author":"Eichenauer","year":"2011","journal-title":"Blood"},{"issue":"21","key":"2019111703541024300_B36","first-page":"2686","article-title":"Frontline therapy of nodular lymphocyte predominant Hodgkin lymphoma with rituximab: the Stanford University experience [abstract]","volume":"118","author":"Advani","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"9","key":"2019111703541024300_B37","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1097\/00043426-200309000-00003","article-title":"Results of little or no treatment for lymphocyte-predominant Hodgkin disease in children and adolescents","volume":"25","author":"Murphy","year":"2003","journal-title":"J Pediatr Hematol Oncol"},{"issue":"11","key":"2019111703541024300_B38","first-page":"2470","article-title":"Surgical resection alone in children with limited stage lymphocyte predominant Hodgkin's lymphoma\u2013the experience of the EuroNet-PHL group [abstract]","volume":"108","author":"Mauz-Koerholz","year":"2006","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"2019111703541024300_B39","doi-asserted-by":"crossref","first-page":"9524","DOI":"10.1200\/jco.2012.30.15_suppl.9524","article-title":"Treatment of pediatric stage IA lymphocyte-predominant Hodgkin lymphoma with surgical resection alone: A report from the Children's Oncology Group","volume":"30","author":"Appel","year":"2012","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111703541024300_B40","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1200\/JCO.2009.26.3293","article-title":"What is the appropriate systemic chemotherapy for lymphocyte-predominant Hodgkin's lymphoma?","volume":"28","author":"Canellos","year":"2010","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111703541024300_B41","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1200\/JCO.2003.12.086","article-title":"Randomized comparison of ABVD and MOPP\/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an Intergroup Trial","volume":"21","author":"Duggan","year":"2003","journal-title":"J Clin Oncol"},{"issue":"21","key":"2019111703541024300_B42","first-page":"2812","article-title":"Outcomes of Nodular Lymphocyte Predominant Hodgkin's Lymphoma (NLPHL) Patients Treated with R-CHOP [abstract]","volume":"116","author":"Fanale","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"11","key":"2019111703541024300_B43","first-page":"644","article-title":"Results of a prospective phase II trial of limited and extended rituximab treatment in nodular lymphocyte predominant Hodgkin's disease (NLPHD) [abstract]","volume":"110","author":"Horning","year":"2007","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"11","key":"2019111703541024300_B44","first-page":"3059","article-title":"Phase I\/II dose-escalation study of tositumomab and iodine I-131 tositumomab for relapsed\/refractory classical or lymphocyte-predominant Hodgkin's Lymphoma: feasibility and initial safety [abstact]","volume":"112","author":"Jacene","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"5","key":"2019111703541024300_B45","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1200\/JCO.2009.24.9516","article-title":"Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin's lymphoma","volume":"28","author":"Al-Mansour","year":"2010","journal-title":"J Clin Oncol"},{"issue":"21","key":"2019111703541024300_B46","first-page":"1525","article-title":"Diffuse large B-cell Transformation in nodular lymphocyte predominant Hodgkin lymphoma: incidence, risk factors and outcomes after a forty-year experience from a single institution [abstract]","volume":"120","author":"Sirop","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"21","key":"2019111703541024300_B47","first-page":"2684","article-title":"Tumor microenvironment in nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) influences occurrence of relapses and progression to large cell lymphoma [abstract]","volume":"116","author":"Bakshi","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"10","key":"2019111703541024300_B48","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1093\/annonc\/mdq063","article-title":"Lymphocyte-predominant Hodgkin lymphoma\u2014clinical features and treatment outcomes from a 30-year experience","volume":"21","author":"Jackson","year":"2010","journal-title":"Ann Oncol"},{"issue":"3","key":"2019111703541024300_B49","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/cncr.24819","article-title":"Nodular, lymphocyte-predominant Hodgkin lymphoma: a long-term study and analysis of transformation to diffuse large B-cell lymphoma in a cohort of 164 patients from the Adult Lymphoma Study Group","volume":"116","author":"Biasoli","year":"2010","journal-title":"Cancer"},{"issue":"11","key":"2019111703541024300_B50","first-page":"3061","article-title":"High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (AHSCT) for lymphocyte predominant Hodgkin's disease [abstract]","volume":"108","author":"Bierman","year":"2006","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"6","key":"2019111703541024300_B51","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.bbmt.2013.03.008","article-title":"High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Nodular Lymphocyte-Predominant Hodgkin Lymphoma","volume":"19","author":"Karuturi","year":"2013","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2013\/1\/406\/1250929\/bep00113000406.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2013\/1\/406\/1250929\/bep00113000406.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T17:05:13Z","timestamp":1597165513000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2013\/1\/406\/20885\/Lymphocytepredominant-Hodgkin-lymphoma-what-is-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,6]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12,6]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2013.1.406","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,6]]}}}